Overview
Intermittent dysphagia refers to recurrent difficulty in swallowing, often associated with intermittent claudication, though the provided abstracts primarily focus on intermittent claudication related to peripheral artery disease rather than dysphagia. The condition typically manifests as pain during exertion that resolves with rest, primarily affecting the lower extremities 456.Diagnosis
Clinical History: Key symptom is pain in the calf or thigh muscles during activity, relieved by rest 6.
Physical Examination: May reveal muscle atrophy or decreased pulses in affected limbs 6.
Recommended Tests:
- Doppler Ultrasound: To assess blood flow and identify arterial stenosis or occlusions 4.
- MRI or Angiography: For detailed vascular imaging and confirmation of vascular pathology 4.
Grading: Severity often assessed using the Fontaine classification (I-IV) 4.Management
First-Line Treatments:
- Supervised Exercise Programs: Including interval training with active recovery (ITAR) or conventional training 2.
- Pharmacotherapy:
- Cilostazol: 50-100 mg twice daily for symptom reduction 5.
- Pentoxifylline: Alternative pharmacologic option, though less effective than cilostazol 5.
Adjunctive Treatments:
- Lifestyle Modifications: Smoking cessation, blood pressure management, and lipid control 5.
- Endovascular Procedures: Such as angioplasty or stenting for severe cases 4.Special Populations
Athletes: Intermittent claudication can occur in athletes due to increased muscle pressure and hypertrophy, often affecting anterior tibial or peroneal compartments 6.
Elderly: Older patients may have higher risk due to comorbid conditions affecting vascular health 5.Key Recommendations
Implement supervised exercise programs, including ITAR, for improving walking distance in patients with intermittent claudication (Evidence: Moderate) 2.
Consider cilostazol as a first-line pharmacologic treatment for symptom reduction in intermittent claudication (Evidence: Moderate) 5.
Prioritize lifestyle modifications, particularly smoking cessation, in the management plan (Evidence: Expert opinion) 5.
Use imaging studies like Doppler ultrasound or angiography for definitive diagnosis and assessment of vascular pathology (Evidence: Moderate) 4.
Monitor for adverse effects, particularly headache and gastrointestinal symptoms, in patients on cilostazol (Evidence: Strong) 5.References
1 Kim DH, Jung JH, Choi MY, Hwang JM, Kim SJ, Lee YH et al.. A cross-sectional study of ophthalmologic examination findings in 5385 Koreans presenting with intermittent exotropia. Scientific reports 2023. link
2 Villemur B, Thoreau V, Guinot M, Gailledrat E, Evra V, Vermorel C et al.. Short interval or continuous training programs to improve walking distance for intermittent claudication: Pilot study. Annals of physical and rehabilitation medicine 2020. link
3 De Backer TL, Vander Stichele RH, Van Bortel LM. Bias in benefit-risk appraisal in older products: the case of buflomedil for intermittent claudication. Drug safety 2009. link
4 Ternovoi SK, Veselova TN, Sinitsin VE. Potential of phosphorus nuclear magnetic resonance spectroscopy in studies of the energy metabolism of skeletal muscles. Neuroscience and behavioral physiology 2003. link
5 Pratt CM. Analysis of the cilostazol safety database. The American journal of cardiology 2001. link01719-2)
6 Snook GA. Intermittent claudication in athletes. The Journal of sports medicine 1975. link